Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib and Nivolumab in ALK-Positive NSCLC
NCT02393625Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2015
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of ceritinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoints: Maximum Tolerated Dose and/or Recommended Dose for Expansion at 6 weeks and Overall Response Rate at 24 weeks. Started May 2015; status: active, not recruiting.
02
Drugs
ceritinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02393625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02393625.